$121 Million is the total value of Casdin Capital, LLC's 25 reported holdings in Q4 2016. The portfolio turnover from Q3 2016 to Q4 2016 was 50.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LOXO | Buy | LOXO ONCOLOGY INC | $11,561,000 | +51.8% | 360,000 | +23.7% | 9.55% | +54.8% |
| FMI | Buy | FOUNDATION MEDICINE INC | $9,664,000 | -0.3% | 546,000 | +31.6% | 7.98% | +1.7% |
| EVH | Buy | EVOLENT HEALTH INCcl a | $8,214,000 | -13.3% | 555,000 | +44.2% | 6.78% | -11.6% |
| ONCE | Buy | SPARK THERAPEUTICS INC | $6,412,000 | +14.2% | 128,500 | +37.4% | 5.30% | +16.5% |
| BLUE | Buy | BLUEBIRD BIO INC | $5,090,000 | +25.2% | 82,500 | +37.5% | 4.20% | +27.7% |
| VYGR | Buy | VOYAGER THERAPEUTICS INC | $4,905,000 | +47.7% | 385,000 | +39.2% | 4.05% | +50.7% |
| GBT | Buy | GLOBAL BLOOD THERAPEUTICS IN | $4,393,000 | -20.6% | 304,000 | +26.7% | 3.63% | -19.0% |
| KITE | Buy | KITE PHARMA INC | $4,215,000 | -16.2% | 94,000 | +4.4% | 3.48% | -14.5% |
| MYOK | Buy | MYOKARDIA INC | $3,432,000 | +31.3% | 265,000 | +65.6% | 2.84% | +33.9% |
| ILMN | New | ILLUMINA INC | $3,201,000 | – | 25,000 | +100.0% | 2.64% | – |
| ALNY | Buy | ALNYLAM PHARMACEUTICALS INC | $3,182,000 | +20.4% | 85,000 | +117.9% | 2.63% | +22.8% |
| CERN | New | CERNER CORP | $3,079,000 | – | 65,000 | +100.0% | 2.54% | – |
| MDRX | Buy | ALLSCRIPTS HEALTHCARE SOLUTN | $2,859,000 | +8.5% | 280,000 | +40.0% | 2.36% | +10.7% |
| AMRS | New | AMYRIS INC | $2,500,000 | – | 3,425,000 | +100.0% | 2.06% | – |
| SYRS | Buy | SYROS PHARMACEUTICALS INC | $2,215,000 | +219.2% | 182,141 | +264.3% | 1.83% | +225.4% |
| GNMX | New | AEVI GENOMIC MEDICINE INC | $1,943,000 | – | 375,000 | +100.0% | 1.60% | – |
| XLRN | New | ACCELERON PHARMA INC | $1,148,000 | – | 45,000 | +100.0% | 0.95% | – |
| GILD | New | GILEAD SCIENCES INC | $895,000 | – | 12,500 | +100.0% | 0.74% | – |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2017-02-14
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| BLUEPRINT MEDICINES CORP | 32 | Q3 2023 | 9.6% |
| ALNYLAM PHARMACEUTICALS INC | 32 | Q3 2023 | 9.9% |
| AGIOS PHARMACEUTICALS INC | 27 | Q2 2022 | 12.1% |
| GLOBAL BLOOD THERAPEUTICS IN | 27 | Q2 2022 | 7.1% |
| FATE THERAPEUTICS INC | 26 | Q3 2023 | 8.3% |
| BIOLIFE SOLUTIONS INC | 22 | Q3 2023 | 14.9% |
| CODEXIS INC | 22 | Q3 2023 | 8.1% |
| SAREPTA THERAPEUTICS INC | 21 | Q3 2023 | 13.6% |
| BLUEBIRD BIO INC | 21 | Q4 2020 | 7.8% |
| ILLUMINA INC | 21 | Q3 2023 | 6.0% |
View Casdin Capital, LLC's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Absci Corp | May 08, 2023 | 4,448,260 | 4.8% |
| CODEXIS, INC.Sold out | February 14, 2023 | 0 | 0.0% |
| DermTech, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Invitae Corp | February 14, 2023 | 9,038,388 | 3.7% |
| Magenta Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Tango Therapeutics, Inc.Sold out | February 14, 2023 | 0 | 0.0% |
| Verve Therapeutics, Inc. | February 14, 2023 | 2,290,571 | 3.7% |
| Tenaya Therapeutics, Inc. | December 07, 2022 | 6,427,200 | 9.9% |
| Fulcrum Therapeutics, Inc. | February 11, 2021 | 1,241,176 | 4.5% |
| Gritstone Oncology, Inc.Sold out | February 11, 2021 | 0 | 0.0% |
View Casdin Capital, LLC's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-17 |
| 13F-HR | 2024-05-15 |
| 4 | 2024-05-15 |
| 4 | 2024-05-02 |
| SC 13G | 2024-04-18 |
| SC 13D/A | 2024-04-08 |
| 4 | 2024-03-28 |
| 3 | 2024-03-25 |
| 4 | 2024-03-25 |
| 4 | 2024-03-20 |
View Casdin Capital, LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.